Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study
An erratum to this article was published (Rheumatology (Oxford), 1 May 2025 ↗)
Authors' conclusion
Patients reported high adherence to medication after 5 years. Non-adherence was related to more flares and less urate target achievement. Younger age and non-European origin were associated with non-adherence.
Study context
- Population
- Patients with gout after a recent flare and serum urate >360 µmol/l (mean age 56.2, 94.5% males, 17.2% with tophi), treated to target with escalating urate lowering therapy (ULT) over one year
- Participants
- 163 patients
- Exposure
- Lowest vs highest Medication Adherence Report Scale (MARS-5) adherence quartile
- Outcome
- Self-reported adherence to ULT (MARS-5, range 5-25)
- Follow-up
- 5 years
Methodological detailsobservational, treat-to-target, 5-year follow-up
- Observational
- Treat-to-target
- 5-year follow-up
Main finding
As reported in the abstract
MARS-5 adherence score
MARS-5 adherence score, median (IQR)
24
22–25
ULT use at 5 years
95.1%
Observational data: associations, not effects.
Further findings
Flare during last year of follow-up · 5 years
P = 0.004
Serum urate treatment target reached · 5 years
P < 0.001
Baseline independent risk factors for non-adherence
- Lower age, OR
- 0.56 (0.39-0.79) (95% CI)
- Non-European origin, OR
- 0.22 (0.06-0.80) (95% CI)
- Lower SF-36 mental health score, OR
- 0.94 (0.91-0.98) (95% CI)
- Less joint pain during last flare, OR
- 0.73 (0.58-0.92) (95% CI)
Original publication
Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study. Rheumatology (Oxford). Published 18 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →